A benefit-risk assessment of inhaled long-acting β2- agonists in the management of obstructive pulmonary disease

Drug Safety

Volumn 27, Issue 10, 2004, Pages 689-715

  Sovani, Milind P ^a   Whale, Christopher I ^a   Tattersfield, Anne E ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; ZAFIRLUKAST;

AGITATION; ANXIETY DISORDER; ASTHMA; BLOOD TOXICITY; BREATHING MUSCLE; BRONCHOSPASM; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEATH; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERANCE; EPIDEMIOLOGICAL DATA; EXERCISE INDUCED ASTHMA; EXERCISE TOLERANCE; FETUS HEART RATE; FETUS MALFORMATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPOKALEMIA; LASSITUDE; LIPOPHILICITY; LUNG FUNCTION; MALAISE; MUSCLE CRAMP; MUSCLE STRENGTH; NOCTURNAL ASTHMA; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SYMPTOM; TACHYCARDIA; TREMOR; VASODILATATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ASTHMA; DELAYED-ACTION PREPARATIONS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RISK ASSESSMENT;

EID: 4344661580     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427100-00001     Document Type: Review

References (150)

1. Jack D. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 1991; 31: 501-14
2. Anderson GP. Long acting inhaled beta-adrenoceptor agonists. The comparative pharmacology of formoterol and salmeterol. In: New drugs in allergy and asthma. Basel: Birkhauser Verlag, 1993
3. van Noord JA, Smeets JJ, Raaijmakers JAM, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684-8
4. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6
5. 2-agonists in asthma. N Engl J Med 1992; 327: 1204-8
6. Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; I: 554-8
7. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833-7
8. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long term treatment with inhaled corticosteroids and beta agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653-9
9. Kraan J, Koeter GH, vd Mark TW, et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628-36
10. 2-agonist treatment. Am Rev Respir Dis 1993; 148: 707-12
11. Hall IP, Tattersfield AE. β-Adrenoceptor agonists. In: Barnes PJ, Rodger IW, Thomson NC, editors. Asthma: basic mechanisms and clinical management. 3rd ed. London: Academic Press, 1999: 651-76
12. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006-11
13. 2-agonist, assessed in airway biopsies and bronchoalverolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493-9
14. Wallin A, Sandström T, Söderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1998; 158: 79-86
15. Kraft M, Wenzel SE, Bettinger CM, et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997; 111: 1249-54
16. Jeffery PK, Venge P, Gizycki MJ, et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378-85
17. Dahl R, Pedersen B, Venge P. Bronchoalveolar lavage studies. Eur Respir Rev 1991; 4: 272-5
18. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma randomized, placebo controlled trial. Can Respir J 1998; 5: 161-8
19. Bacci E, Di Franco A, Bartoli ML, et al. Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J 2002; 20: 66-72
20. 2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275-82
21. Boulet L-P, Chakir J, Milot J, et al. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clin Exp Allergy 2001; 31: 430-7
22. 2-adrenergic receptor. J Biol Chem 1996; 271: 24029-35
23. Palmqvist M, Ibsen T, Mellén TI, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244-9
24. Smyth ET, Pavord ID, Wong CS, et al. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993; 306: 543-5
25. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-6
26. Korosec M, Novak RD, Myers E, et al. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999; 107: 209-13
27. Dollery C, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone, 1999
28. Bennett JA, Harrison TW, Tattersfield AE. The contribution of the swallowed fraction of an inhaled dose of salmeterol to its systemic effects. Eur Respir J 1999; 13: 445-8
29. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-203
30. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-9
31. Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma. Am J Respir Crit Care Med 1995; 152: 1170-4
32. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-8
33. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141-6
34. Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49: 771-4
35. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650-6
36. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting β-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178-84
37. Jones KP. Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. Thorax 1994; 49: 971-5
38. Boyd G, on behalf of a UK Study Group. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. Eur Respir J 1995; 8: 1494-8
39. Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1995; 51: 1100-4
40. Wilding P, Clark M, Thompson Coon J, et al. Effect of long term treatment with salmeterol on asthma control. BMJ 1997; 314: 1441-6
41. Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: 188-95
42. Lockey RF, DuBuske M, Friedman B, et al. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999; 115: 666-73
43. Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 1999; 116: 595-602
44. Kemp JP, DeGraff AC, Pearlman DS, et al. A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine. J Allergy Clin Immunol 1999; 104: 1189-97
45. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001; 285: 2594-603
46. 2- agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001; 285: 2583-93
47. D'Urzo AD, Chapman KR, Cartier A, et al. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001; 119: 714-9
48. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-7
49. Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155-7
50. Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148-53
51. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-7
52. Rutten-van Mölken MPMH, Custers F, Vandoorslaer EKA, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8 (6): 888-98
53. Faurschou P, Steffensen I, Jacques L, et al. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. Eur Respir J 1996; 9: 1885-90
54. Boulet L-P, Laviiolette M, Boucher S, et al. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immunol 1997; 99: 13-21
55. Wenzel SE, Lumry W, Manning M, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998; 80: 463-70
56. Pearlman DS, Chervinski P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420-5
57. D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412-6
58. Juniper EF, Johnston PR, Borkhoff CM, et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995; 151: 66-70
59. Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am J Respir Crit Care Med 1996; 154: 324-8
60. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53: 744-52
61. Kemp J, Wolfe J, Grady J, et al. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clin Ther 1998; 20: 270-82
62. Schreurs AJM, Sinninghe Damsté HEJ, de Graaff CS, et al. A dose-response study with formoterol Tubuhaler® as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9: 1678-83
63. van der Molen T, Postma DS, Turner MO, et al. Effects of the long-acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-9
64. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-11
65. van der Molen T, Sears MR, Graaff CS, et al. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Eur Respir J 1998; 12: 30-4
66. Garcia R, Guerra P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Investig Allergol Clin Immunol 2001; 11: 176-82
67. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392-7
68. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-8
69. Price D, Dutchman D, Mawson A, et al. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 2002; 57: 791-8
70. 2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259-61
71. Kesten S, Chapman KR, Broker I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-5
72. Arvidsson P, Larsson S, Lofdahl C-G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-73
73. 2-agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992; 101: 1019-22
74. Stålenheim G, Wegener T, Grettve L, et al. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994; 61: 305-9
75. Thomson NC, Angus R, Quebe-Fehling E, et al. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998; 92: 562-7
76. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999; 103: 427-35
77. Ekström T, Ringdal N, Sobradillo V, et al. Low-dose formoterol Turbuhaler® (Oxis®) bid, a 3-month placebo-controlled comparison with terbutaline (qid). Respir Med 1998; 92: 1040-5
78. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoteril dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19-27
79. 2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497-504
80. 2-agonist. BMJ 1990; 301: 1365-8
81. Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 μg bid and on-demand salbutamol in moderate persistent asthma. Respir Med 2001; 94: 64-70
82. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-30
83. Selby C, Engleman HM, Fitzpatrick MF, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma? Am J Respir Crit Care Med 1997; 155: 104-8
84. Pollard SJ, Spector SL, Yancey SW, et al. Salmeterol versus theophylline in the treatment of asthma. Ann Allergy Asthma Immunol 1997; 78: 457-64
85. Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994; 88: 599-607
86. Paggiaro PL, Giannini D, Di Franco A, et al. Comparison of inhaled salmeterol and individually dose-tritrated slow-release theophylline in patients with reversible airway obstruction. Eur Respir J 1996; 9: 1689-95
87. Wiegand L, Mende CN, Zaidel G, et al. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest 1999; 115: 1525-32
88. Yurdakul AS, Çalisir HC, Tunctan B, et al. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med 2002; 96: 322-9
89. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075-80
90. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423-30
91. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-95
92. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral monetlukast in asthma. Respir Med 2003; 97: 234-41
93. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327: 891-5
94. Villaran C, O'Neill SH, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999; 104: 547-53
95. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern Med 2000; 132: 97-104
96. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-73
97. Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14: 627-32
98. Tattersfield AE, Löfdahl G-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-61
99. Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20: 859-66
100. Pauwels RA, Sears MR, Campbell M, et al. Formoteril as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787-94
101. Peters JI, Shelledy DC, Jones AP, et al. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. Chest 2000; 118: 313-20
102. Ritz M, Thorens JB, Arnold-Ketterer M, et al. Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attach. Intensive Care Med 1997; 23: 1225-30
103. Malolepszy J, Böszörményi Nagy G, Selroos O, et al. Safety of formoterol turbuhaler® at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 2001; 18: 928-34
104. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMD1 plus spacer in patients with acute severe asthma. Respir Med 2003; 97: 1067-74
105. Palmer JBD, Stuart AM, Shepherd GL, et al. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100μg) with salmeterol (50μg). Respir Med 1992; 86: 409-17
106. Woolcock A, Lundbak B, Ringdal N, et al. Comparison of the addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153 (5): 1481-8
107. VervIoet D, Ekström T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998; 92: 830-42
108. 2-agonists: eformoterol via Turbohaler® and salmeterol via pressurized metered dose inhaler or Accuhaler®, in mild to moderate asthmatics. Respir Med 1999; 93: 236-44
109. Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther 2001; 23: 1529-41
110. Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 2002; 121: 1401-6
111. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750-4
112. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-93
113. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21
114. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9
115. Weiner P, Magadle R, Berar-Yanay N, et al. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnoea in patients with advanced COPD. Chest 2000; 118: 672-8
116. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002; 9 (3): 178-85
117. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, contrllled, 3-month trial. Eur Respir J 2002; 19: 936-43
118. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91
119. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
120. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56
121. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9
122. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65
123. Rutten-van Mölken M, Roos B, van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995-1003
124. van Noord JA, de Munck DRAJ, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-85
125. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84
126. 2-adrenergic agonist, salmeferol xinafoate, in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 163: 1087-92
127. Wadbo M, Löfdahl C-G, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138-46
128. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55
129. Di Lorenzo G, Morici G, Drago A, et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther 1998; 20 (6): 1130-48
130. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-70
131. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058-69
132. D'Urzo AD, Cristina De Salvo M, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347-56
133. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97: 1014-20
134. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138 (4): 850-5
135. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70-4
136. Tötterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via turbuhaler® for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573-9
137. Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817-24
138. Chervinsky P, Goldberg P, Galant S, et al. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. Chest. 1999; 115: 642-8
139. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411-5
140. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993; 87: 227-8
141. Wilkinson JRW, Roberts JA, Bradding P, et al. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992; 305: 931-2
142. Shaheen MZ, Ayres JG, Benincasa C. Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. Eur Respir J 1994; 7: 2160-4
143. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49: 247-50
144. Wilton LV, Shakir SA. A postmarketing surveillance study of formoterol (Foradil®). Drug Saf 2002; 25: 213-23
145. US Food and Drug Association. Letters from GlaxoSmithKline Jan 2003, Aug 2003 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2003/ serevent [Accessed 2004 Jun]
146. US Food and Drug Association. Labeling changes for drug products that contain salmeterol. FDA talk paper TO3-62 Aug 14, 2003 [online]. Available from URL: http://www.fda.gov/topics/2003/ANS01248.html [Accessed 2004 Jun]
147. Lanes SF, García Rodríguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 683-6
148. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53: 7-13
149. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160: 594-9
150. Wareham NJ, Harrison BDW, Jenkins PF, et al. A district confidential enquiry into deaths due to asthma. Thorax 1993; 48: 1117-20